MeSH term
Frequency | Condition_Probility | Female | 70 | 0.0 |
Humans | 233 | 0.0 |
Pregnancy | 2 | 0.0 |
Indoles/*therapeutic use | 3 | 2.0 |
Acute Disease | 70 | 2.0 |
Adolescent | 31 | 0.0 |
Adult | 55 | 0.0 |
Aged | 38 | 0.0 |
Antineoplastic Combined Chemotherapy Protocols/therapeutic use | 5 | 1.0 |
Disease-Free Survival | 9 | 0.0 |
Gene Expression | 11 | 0.0 |
Leukemia, Myeloid/drug therapy/*genetics | 2 | 20.0 |
Middle Aged | 58 | 0.0 |
Neoplasm Proteins/*genetics | 9 | 0.0 |
Prognosis | 40 | 0.0 |
Research Support, Non-U.S. Gov't | 165 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 17 | 0.0 |
Survival Analysis | 13 | 0.0 |
Treatment Outcome | 14 | 0.0 |
Tumor Markers, Biological/*genetics | 2 | 1.0 |
Base Sequence | 23 | 0.0 |
DNA Mutational Analysis/methods | 3 | 1.0 |
DNA, Neoplasm/genetics | 6 | 0.0 |
Gene Expression Profiling/methods | 2 | 2.0 |
Leukemia, Myeloid/*genetics | 14 | 9.0 |
Male | 65 | 0.0 |
Molecular Sequence Data | 36 | 0.0 |
*Mutation | 29 | 0.0 |
Proto-Oncogene Proteins/*genetics | 63 | 6.0 |
Receptor Protein-Tyrosine Kinases/*genetics | 61 | 16.0 |
Child | 22 | 0.0 |
Leukemia, Myelocytic, Acute/*genetics | 11 | 9.0 |
*Tandem Repeat Sequences | 9 | 8.0 |
Case-Control Studies | 3 | 0.0 |
DNA Mutational Analysis | 6 | 0.0 |
Gene Frequency | 6 | 0.0 |
Tandem Repeat Sequences/*genetics | 4 | 4.0 |
English Abstract | 4 | 0.0 |
Membrane Proteins/physiology | 2 | 2.0 |
Signal Transduction/*physiology | 2 | 0.0 |
Chromosome Aberrations | 3 | 0.0 |
Cohort Studies | 5 | 0.0 |
Cytogenetic Analysis | 4 | 3.0 |
Animals | 71 | 0.0 |
Immunophenotyping | 13 | 0.0 |
Membrane Proteins/*genetics | 4 | 0.0 |
Mice | 51 | 0.0 |
Mice, Inbred C3H | 3 | 0.0 |
Mice, Transgenic | 4 | 0.0 |
Neoplasm Transplantation | 5 | 0.0 |
Oncogene Proteins, Fusion/*genetics | 3 | 1.0 |
Research Support, U.S. Gov't, P.H.S. | 63 | 0.0 |
Disease Progression | 3 | 0.0 |
Down-Regulation | 5 | 0.0 |
Genes, ras/genetics | 3 | 2.0 |
Mutation | 33 | 0.0 |
Proto-Oncogene Proteins/genetics | 5 | 0.0 |
RNA, Messenger/metabolism | 8 | 0.0 |
RNA, Neoplasm/metabolism | 2 | 2.0 |
Receptor Protein-Tyrosine Kinases/genetics | 5 | 3.0 |
Survival Rate | 7 | 0.0 |
Cell Transformation, Neoplastic | 6 | 1.0 |
Receptors, Cell Surface/metabolism | 2 | 0.0 |
Child, Preschool | 13 | 0.0 |
Infant | 10 | 0.0 |
Loss of Heterozygosity | 2 | 0.0 |
*Point Mutation | 7 | 0.0 |
Tandem Repeat Sequences | 19 | 12.0 |
Aged, 80 and over | 12 | 0.0 |
Cell Culture Techniques/methods | 2 | 0.0 |
Cell Differentiation | 7 | 0.0 |
Cell Lineage | 4 | 0.0 |
DNA Fingerprinting | 2 | 1.0 |
Membrane Proteins/pharmacology | 6 | 13.0 |
Age Factors | 2 | 0.0 |
Amino Acid Substitution | 4 | 0.0 |
Enzyme Activation/genetics | 4 | 4.0 |
Genetic Screening | 3 | 0.0 |
Point Mutation | 8 | 0.0 |
Prevalence | 2 | 0.0 |
Proto-Oncogene Proteins/*genetics/metabolism | 4 | 2.0 |
Receptor Protein-Tyrosine Kinases/*genetics/metabolism | 4 | 6.0 |
Models, Biological | 3 | 0.0 |
Protein-Tyrosine Kinase/*genetics | 5 | 2.0 |
Signal Transduction | 15 | 0.0 |
Antineoplastic Agents/pharmacology | 4 | 0.0 |
Apoptosis/drug effects | 9 | 1.0 |
Bone Marrow Cells/enzymology/pathology | 3 | 60.0 |
Cell Survival/drug effects | 3 | 0.0 |
Enzyme Inhibitors/*pharmacology | 13 | 1.0 |
Kinetics | 4 | 0.0 |
Mice, Inbred BALB C | 7 | 0.0 |
Mitogen-Activated Protein Kinase 3 | 3 | 0.0 |
Proto-Oncogene Proteins/*antagonists & inhibitors/*genetics | 4 | 100.0 |
Receptor Protein-Tyrosine Kinases/*antagonists & inhibitors/*genetics | 4 | 100.0 |
Transplantation, Heterologous | 4 | 0.0 |
Tumor Cells, Cultured | 29 | 0.0 |
Cells, Cultured | 20 | 0.0 |
Dendritic Cells/*immunology | 2 | 0.0 |
Membrane Proteins/*therapeutic use | 3 | 42.0 |
Leukocyte Count | 10 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 7 | 0.0 |
src Homology Domains | 5 | 0.0 |
Antineoplastic Agents/*pharmacology | 5 | 0.0 |
Enzyme Inhibitors/pharmacology | 8 | 0.0 |
Leukemia, Myeloid/genetics/*metabolism/pathology | 2 | 28.0 |
Neoplasm Proteins/metabolism | 2 | 0.0 |
P-Glycoprotein/*metabolism | 2 | 2.0 |
Proto-Oncogene Proteins/antagonists & inhibitors/*genetics | 3 | 60.0 |
Receptor Protein-Tyrosine Kinases/antagonists & inhibitors/*genetics | 3 | 75.0 |
DNA-Binding Proteins/genetics | 2 | 0.0 |
*Gene Expression Regulation, Leukemic | 3 | 3.0 |
Gene Rearrangement | 4 | 0.0 |
Genotype | 2 | 0.0 |
Indoles/*pharmacology | 6 | 6.0 |
Phenotype | 5 | 0.0 |
Transcription Factors/genetics | 4 | 0.0 |
Antigens, CD/metabolism | 2 | 0.0 |
Cell Differentiation/immunology | 2 | 0.0 |
Comparative Study | 22 | 0.0 |
Gene Expression Regulation, Neoplastic | 4 | 0.0 |
Proto-Oncogene Protein c-kit/metabolism | 3 | 6.0 |
Proto-Oncogene Proteins/metabolism | 4 | 0.0 |
Receptor Protein-Tyrosine Kinases/metabolism | 6 | 2.0 |
Cell Differentiation/drug effects | 5 | 0.0 |
Cell Division/drug effects | 16 | 0.0 |
Colony-Forming Units Assay | 7 | 1.0 |
Fetal Blood/*cytology | 3 | 1.0 |
Hematopoietic Stem Cells/*physiology | 2 | 1.0 |
Antigens, CD34 | 4 | 0.0 |
Cell Division | 15 | 0.0 |
Flow Cytometry | 21 | 0.0 |
Hematopoiesis | 4 | 1.0 |
*Hematopoietic Stem Cell Transplantation | 2 | 0.0 |
Mice, SCID | 6 | 0.0 |
Time Factors | 13 | 0.0 |
Blotting, Western | 8 | 0.0 |
Cell Cycle/drug effects | 4 | 0.0 |
Computer Systems | 2 | 3.0 |
Drug Synergism | 4 | 0.0 |
Granulocyte Colony-Stimulating Factor/*pharmacology | 2 | 1.0 |
Membrane Proteins/*pharmacology | 8 | 17.0 |
Phosphorylation/drug effects | 6 | 0.0 |
Precipitin Tests | 5 | 0.0 |
Protein Processing, Post-Translational/drug effects | 3 | 2.0 |
Tumor Cells, Cultured/drug effects | 7 | 1.0 |
Delayed-Action Preparations | 2 | 1.0 |
Protein-Tyrosine Kinase/*antagonists & inhibitors | 3 | 1.0 |
Swine | 2 | 0.0 |
Amino Acid Sequence | 25 | 0.0 |
Cell Line | 22 | 0.0 |
Cloning, Molecular | 7 | 0.0 |
Disease Models, Animal | 3 | 0.0 |
Leukocytosis | 2 | 25.0 |
Proto-Oncogene Proteins/chemistry/*genetics | 4 | 17.0 |
Receptor Protein-Tyrosine Kinases/chemistry/*genetics | 4 | 23.0 |
Transfection | 22 | 0.0 |
Vascular Endothelial Growth Factor Receptor-1 | 4 | 1.0 |
DNA-Binding Proteins/*metabolism | 4 | 0.0 |
Gene Duplication | 10 | 6.0 |
*Milk Proteins | 13 | 2.0 |
Phosphorylation | 30 | 0.0 |
Trans-Activators/*metabolism | 3 | 0.0 |
DNA-Binding Proteins/*genetics | 8 | 0.0 |
Karyotyping | 11 | 0.0 |
Leukemia, Myeloid/etiology/*genetics | 2 | 18.0 |
*Proto-Oncogenes | 11 | 1.0 |
Tandem Repeat Sequences/genetics | 6 | 12.0 |
*Transcription Factors | 7 | 0.0 |
Translocation, Genetic | 6 | 0.0 |
Hematopoiesis/drug effects | 4 | 5.0 |
Hematopoietic Stem Cells/drug effects | 3 | 5.0 |
Recombinant Proteins/pharmacology | 7 | 0.0 |
Neoplasm Proteins/genetics | 2 | 0.0 |
Membrane Proteins/genetics/*metabolism | 2 | 0.0 |
Sequence Analysis, DNA | 4 | 0.0 |
Tissue Distribution | 3 | 0.0 |
Sensitivity and Specificity | 3 | 0.0 |
Blood Cell Count | 2 | 0.0 |
Enzyme Activation/drug effects/genetics | 2 | 9.0 |
Mutation/*genetics | 11 | 0.0 |
Phosphotyrosine/metabolism | 2 | 0.0 |
Cell Cycle | 3 | 0.0 |
DNA-Binding Proteins/metabolism | 7 | 0.0 |
Gene Expression Regulation | 4 | 0.0 |
Models, Molecular | 4 | 0.0 |
Protein Structure, Tertiary | 14 | 0.0 |
Proto-Oncogene Proteins/chemistry/*genetics/*metabolism | 3 | 25.0 |
Receptor Protein-Tyrosine Kinases/chemistry/*genetics/*metabolism | 3 | 37.0 |
Trans-Activators/metabolism | 8 | 0.0 |
Proto-Oncogene Proteins/*metabolism | 5 | 0.0 |
Receptor Protein-Tyrosine Kinases/*metabolism | 9 | 3.0 |
Retrospective Studies | 7 | 0.0 |
Stem Cell Factor | 3 | 3.0 |
Leukemia, Myeloid/*drug therapy/enzymology/genetics | 2 | 66.0 |
Alleles | 6 | 0.0 |
*Gene Duplication | 12 | 8.0 |
Bone Marrow/pathology | 7 | 1.0 |
Receptors, Cell Surface/genetics | 9 | 8.0 |
Risk Factors | 5 | 0.0 |
Genes, ras/*genetics | 4 | 4.0 |
Follow-Up Studies | 4 | 0.0 |
Polymerase Chain Reaction | 24 | 0.0 |
Reproducibility of Results | 2 | 0.0 |
*Chromosome Aberrations | 3 | 0.0 |
Cytogenetics | 3 | 3.0 |
Myelodysplastic Syndromes/*genetics | 5 | 7.0 |
Protein-Tyrosine Kinase/antagonists & inhibitors | 4 | 1.0 |
Tyrphostins/pharmacology | 4 | 2.0 |
Dose-Response Relationship, Drug | 6 | 0.0 |
Proto-Oncogene Proteins/*antagonists & inhibitors | 4 | 16.0 |
Receptor Protein-Tyrosine Kinases/*antagonists & inhibitors | 7 | 16.0 |
Tyrosine/metabolism | 3 | 0.0 |
Tyrphostins/*pharmacology | 2 | 8.0 |
Aspartic Acid/genetics | 2 | 3.0 |
Leukemia, Myeloid/*genetics/mortality | 4 | 57.0 |
Proto-Oncogene Protein c-kit/genetics | 2 | 5.0 |
Rats | 3 | 0.0 |
Sequence Homology, Amino Acid | 8 | 0.0 |
Statistics, Nonparametric | 2 | 0.0 |
Exons | 5 | 0.0 |
Polymorphism, Single-Stranded Conformational | 3 | 0.0 |
Oncogene Proteins, Fusion/genetics | 5 | 5.0 |
Antineoplastic Agents/therapeutic use | 2 | 0.0 |
Bone Marrow/*pathology | 2 | 1.0 |
Remission Induction | 7 | 1.0 |
Killer Cells, Natural/immunology | 2 | 0.0 |
Ligands | 11 | 0.0 |
Lymphocyte Activation/immunology | 2 | 0.0 |
Mice, Inbred C57BL | 9 | 0.0 |
T-Lymphocytes, Cytotoxic/immunology | 2 | 0.0 |
Binding Sites | 6 | 0.0 |
DNA, Complementary/genetics | 2 | 0.0 |
Neoplasm Proteins/genetics/metabolism | 2 | 1.0 |
Piperazines/*pharmacology | 2 | 3.0 |
Sequence Alignment | 4 | 0.0 |
*Amino Acid Substitution | 2 | 2.0 |
Aspartic Acid/chemistry | 2 | 6.0 |
COS Cells | 5 | 0.0 |
Cell Transformation, Neoplastic/genetics | 4 | 1.0 |
Cercopithecus aethiops | 2 | 0.0 |
Codon/genetics | 5 | 1.0 |
Recombinant Fusion Proteins/physiology | 2 | 0.0 |
Bone Marrow | 2 | 5.0 |
Granulocyte Colony-Stimulating Factor/pharmacology | 3 | 1.0 |
Hematopoietic Stem Cells/cytology/*drug effects | 2 | 3.0 |
Interleukin-3/pharmacology | 7 | 2.0 |
Interleukin-6/pharmacology | 2 | 0.0 |
Signal Transduction/*drug effects | 3 | 0.0 |
Stem Cell Factor/pharmacology | 4 | 2.0 |
Electrophoresis, Polyacrylamide Gel | 3 | 0.0 |
Colony-Stimulating Factors/pharmacology | 2 | 4.0 |
DNA-Binding Proteins/*physiology | 2 | 0.0 |
Mice, Knockout | 2 | 0.0 |
Proto-Oncogene Proteins/*physiology | 5 | 2.0 |
Receptor Protein-Tyrosine Kinases/*physiology | 5 | 7.0 |
*Signal Transduction | 4 | 0.0 |
Trans-Activators/*physiology | 2 | 0.0 |
Sequence Deletion | 5 | 0.0 |
Transduction, Genetic | 2 | 0.0 |
Leukemia, Myelocytic, Acute/metabolism | 3 | 27.0 |
Receptor Protein-Tyrosine Kinases/chemistry/*physiology | 2 | 28.0 |
Cluster Analysis | 2 | 1.0 |
Leukemia, Myeloid/*diagnosis/genetics | 2 | 66.0 |
Oligonucleotide Array Sequence Analysis | 3 | 0.0 |
Predictive Value of Tests | 2 | 0.0 |
Bone Marrow/immunology | 2 | 1.0 |
Interleukin-7/pharmacology | 2 | 4.0 |
Antigens, CD/analysis | 2 | 0.0 |
Mice, Inbred NOD | 4 | 1.0 |
Bone Marrow Transplantation | 5 | 1.0 |
Piperazines/pharmacology | 2 | 1.0 |
Proto-Oncogene Proteins/*antagonists & inhibitors/genetics | 6 | 66.0 |
Receptor Protein-Tyrosine Kinases/*antagonists & inhibitors/genetics | 6 | 85.0 |
Transplantation, Homologous | 3 | 0.0 |
Cell Division/genetics | 2 | 0.0 |
Flavonoids/pharmacology | 2 | 0.0 |
Growth Inhibitors/pharmacology | 2 | 1.0 |
Mutation/genetics | 3 | 0.0 |
Proto-Oncogene Proteins/genetics/*metabolism | 4 | 1.0 |
Receptor Protein-Tyrosine Kinases/genetics/*metabolism | 4 | 3.0 |
Repetitive Sequences, Amino Acid | 2 | 1.0 |
Gene Transfer Techniques | 2 | 0.0 |
Membrane Proteins/*metabolism | 8 | 1.0 |
Reverse Transcriptase Polymerase Chain Reaction/methods | 2 | 0.0 |
Genes, myc | 2 | 0.0 |
Chromosome Mapping | 8 | 0.0 |
Gene Therapy | 4 | 1.0 |
In Vitro | 3 | 0.0 |
Clinical Trials | 5 | 0.0 |
Infant, Newborn | 5 | 0.0 |
RNA, Messenger/analysis | 4 | 0.0 |
*Adaptor Proteins, Signal Transducing | 4 | 0.0 |
*Adaptor Proteins, Vesicular Transport | 4 | 1.0 |
Enzyme Activation | 5 | 0.0 |
Phosphoric Monoester Hydrolases/*metabolism | 2 | 2.0 |
Proteins/*metabolism | 3 | 0.0 |
Retroviridae/genetics | 3 | 0.0 |
ADP-ribosyl Cyclase | 6 | 1.0 |
*Antigens, CD | 5 | 0.0 |
Cell Division/physiology | 3 | 0.0 |
Cell Survival | 3 | 0.0 |
Hematopoietic Stem Cells/cytology/*metabolism | 5 | 20.0 |
Antigens, CD34/metabolism | 5 | 1.0 |
Genetic Vectors | 2 | 0.0 |
Hematopoietic Stem Cell Mobilization | 2 | 2.0 |
Antigens, CD34/*analysis | 4 | 1.0 |
Apoptosis/*drug effects | 3 | 0.0 |
Cell Count | 2 | 0.0 |
Hematopoietic Stem Cells/*cytology/immunology | 3 | 3.0 |
Proto-Oncogene Proteins/*pharmacology | 2 | 14.0 |
Receptor Protein-Tyrosine Kinases/*pharmacology | 2 | 50.0 |
Stem Cell Factor/*pharmacology | 5 | 8.0 |
Thrombopoietin/*pharmacology | 3 | 3.0 |
Antigens, Differentiation/analysis | 4 | 1.0 |
NAD+ Nucleosidase/analysis | 2 | 4.0 |
DNA Primers | 8 | 0.0 |
Proto-Oncogene Protein c-kit/*metabolism | 3 | 6.0 |
RNA, Messenger/genetics | 6 | 0.0 |
Leukemia, Lymphocytic, Acute/*genetics | 2 | 2.0 |
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use | 3 | 0.0 |
Apoptosis | 2 | 0.0 |
Cytokines/pharmacology | 3 | 0.0 |
Leukemia, Myeloid/*metabolism | 2 | 6.0 |
Erythropoiesis/drug effects | 2 | 4.0 |
Biological Markers | 3 | 0.0 |
Neoplasm, Residual/diagnosis/genetics | 2 | 66.0 |
In Situ Hybridization, Fluorescence | 6 | 0.0 |
Staurosporine/*analogs & derivatives/pharmacology | 2 | 28.0 |
Introns | 2 | 0.0 |
Spleen/cytology | 2 | 1.0 |
Cell Line, Tumor | 10 | 0.0 |
Leukemia/*genetics/pathology | 2 | 11.0 |
Neoplasm Proteins/biosynthesis/genetics | 2 | 1.0 |
*Translocation, Genetic | 3 | 0.0 |
Indoles/*pharmacology/therapeutic use | 2 | 18.0 |
Membrane Proteins/blood | 2 | 5.0 |
Pyrroles/*pharmacology/therapeutic use | 2 | 22.0 |
Leukemia, Myeloid/*genetics/metabolism | 3 | 25.0 |
Receptor Protein-Tyrosine Kinases/genetics/*physiology | 2 | 7.0 |
Hematopoiesis/*drug effects | 4 | 4.0 |
Culture Media, Serum-Free | 4 | 1.0 |
Erythropoietin/pharmacology | 2 | 1.0 |
1-Phosphatidylinositol 3-Kinase/metabolism | 3 | 0.0 |
Membrane Proteins/*physiology | 3 | 2.0 |
Phosphotyrosine/analysis | 3 | 5.0 |
Recombinant Proteins/metabolism | 3 | 0.0 |
Antibodies, Monoclonal | 4 | 0.0 |
Fetal Blood/cytology | 4 | 2.0 |
Receptors, Interleukin-6/metabolism | 2 | 7.0 |
Blast Crisis/genetics | 2 | 10.0 |
RNA, Messenger/*metabolism | 2 | 0.0 |
Cell Separation | 4 | 0.0 |
*Repetitive Sequences, Nucleic Acid | 3 | 0.0 |
Antigens, CD34/analysis | 6 | 0.0 |
Bone Marrow Cells | 4 | 0.0 |
Signal Transduction/drug effects | 3 | 0.0 |
Leukemia, Promyelocytic, Acute/*genetics | 2 | 4.0 |
Multigene Family | 4 | 0.0 |
RNA, Neoplasm/genetics | 2 | 0.0 |
Granulocyte-Macrophage Colony-Stimulating Factor/pharmacology | 3 | 0.0 |
Phagocytosis | 2 | 0.0 |
*Hematopoiesis | 2 | 1.0 |
Transforming Growth Factor beta/*metabolism | 2 | 0.0 |
Tumor Necrosis Factor-alpha/metabolism | 2 | 0.0 |
Bone Marrow/metabolism | 5 | 4.0 |
*Bone Marrow Cells | 3 | 1.0 |
Fetal Blood/*cytology/metabolism | 2 | 40.0 |
Proto-Oncogene Proteins/*biosynthesis | 2 | 1.0 |
Receptor Protein-Tyrosine Kinases/*biosynthesis | 2 | 3.0 |
Hematopoietic Stem Cells/*cytology/drug effects | 2 | 2.0 |
Cytokines/*pharmacology | 2 | 0.0 |
CCAAT-Enhancer-Binding Protein-alpha/genetics | 2 | 50.0 |
Gene Expression Regulation, Leukemic | 7 | 7.0 |
Up-Regulation | 3 | 0.0 |
Enzyme Inhibitors/*pharmacology/therapeutic use | 2 | 6.0 |
*Chromosomes, Human, Pair 16 | 2 | 0.0 |
Proto-Oncogene Proteins/biosynthesis/*genetics | 2 | 3.0 |
Receptor Protein-Tyrosine Kinases/biosynthesis/*genetics | 2 | 10.0 |
Transcription, Genetic | 2 | 0.0 |
Proto-Oncogene Proteins/*biosynthesis/genetics/physiology | 3 | 37.0 |
Hematopoietic Stem Cells/*metabolism | 2 | 1.0 |
Receptor Protein-Tyrosine Kinases/analysis/*biosynthesis | 2 | 28.0 |
Leukemia, Myelocytic, Acute/*metabolism | 2 | 11.0 |
Leukemia | 2 | 2.0 |
Polymerase Chain Reaction/*methods | 2 | 0.0 |
*Inversion, Chromosome | 2 | 2.0 |
Recurrence | 8 | 0.0 |
DNA Primers/chemistry | 4 | 0.0 |
DNA Probes | 3 | 0.0 |
Chromosomes, Human, Pair 13 | 2 | 1.0 |
*Gene Expression | 3 | 0.0 |
Receptor Protein-Tyrosine Kinases/*biosynthesis/genetics/physiology | 2 | 50.0 |
Blotting, Northern | 5 | 0.0 |
Hamsters | 3 | 0.0 |
*Cell Differentiation | 2 | 0.0 |
Leukemia/metabolism | 2 | 8.0 |
Leukemia/*genetics | 2 | 1.0 |
Chromatography, High Pressure Liquid | 2 | 0.0 |
Drug Stability | 2 | 0.0 |
Particle Size | 2 | 0.0 |
Solubility | 3 | 0.0 |
Mice/*genetics | 2 | 0.0 |
Protein Conformation | 2 | 0.0 |
Mice, Nude | 5 | 0.0 |
Pyrroles/*therapeutic use | 2 | 5.0 |
*Chromosomes, Human, Pair 13 | 5 | 2.0 |
Hematopoietic Stem Cells/metabolism | 2 | 1.0 |
Exons/genetics | 2 | 0.0 |
Mutation, Missense | 4 | 0.0 |
Polymerase Chain Reaction/methods | 3 | 0.0 |
Protein Binding | 2 | 0.0 |
Membrane Proteins/genetics | 2 | 0.0 |
Leukemia, Myelocytic, Acute/*genetics/pathology | 2 | 6.0 |
Polymorphism, Restriction Fragment Length | 2 | 0.0 |
DNA, Complementary/metabolism | 3 | 0.0 |
Protein-Tyrosine Kinase/*genetics/metabolism | 2 | 4.0 |
Exons/*genetics | 2 | 0.0 |
B-Lymphocytes/metabolism | 2 | 1.0 |
Receptors, Cell Surface/*genetics | 4 | 1.0 |
CHO Cells | 2 | 0.0 |
Nucleic Acid Hybridization | 2 | 0.0 |
Sequence Homology, Nucleic Acid | 2 | 0.0 |
Leukemia, Lymphocytic, Acute, L1/*genetics | 2 | 5.0 |
Oncogene Proteins, Fusion | 2 | 15.0 |
Blast Crisis/pathology | 2 | 20.0 |
Mitogen-Activated Protein Kinases/metabolism | 3 | 0.0 |
Leukemia, Myeloid/*genetics/*therapy | 2 | 100.0 |
DNA, Neoplasm/analysis | 3 | 0.0 |
RNA, Neoplasm/analysis | 2 | 0.0 |
Drug Resistance, Neoplasm | 2 | 0.0 |
Mutagenesis | 2 | 0.0 |
Protein-Tyrosine Kinase/metabolism | 2 | 0.0 |
Pyrroles/*pharmacology | 2 | 4.0 |
Rats, Sprague-Dawley | 2 | 0.0 |
Transcription Factors/*genetics | 2 | 0.0 |
Models, Genetic | 3 | 0.0 |
Enzyme Inhibitors/therapeutic use | 2 | 2.0 |
Vascular Endothelial Growth Factor A | 2 | 0.0 |
Vascular Endothelial Growth Factors | 2 | 0.0 |
Leukemia, Myeloid/*drug therapy/*genetics | 2 | 50.0 |
Pyrimidines/pharmacology | 2 | 1.0 |
*Apoptosis | 2 | 0.0 |
Immunoblotting | 3 | 0.0 |
Green Fluorescent Proteins | 2 | 0.0 |
Interleukin-3/metabolism | 4 | 13.0 |
Indoles/pharmacology | 2 | 0.0 |
Trisomy | 2 | 1.0 |
Incidence | 2 | 0.0 |
Stem Cell Factor/genetics | 2 | 22.0 |
Gene Deletion | 2 | 0.0 |
Signal Transduction/genetics | 2 | 0.0 |
Drug Resistance | 2 | 0.0 |
Protein Processing, Post-Translational | 2 | 0.0 |
Staurosporine/*analogs & derivatives/*pharmacology | 3 | 37.0 |
Point Mutation/*genetics | 2 | 0.0 |
Receptors, Cell Surface/antagonists & inhibitors | 2 | 16.0 |
